These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27284470)

  • 1. Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience.
    Sahu A; Ramaswamy A; Ostwal V
    J Gastrointest Oncol; 2016 Jun; 7(3):380-6. PubMed ID: 27284470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
    Saif MW; Syrigos K; Mehra R; Mattison LK; Diasio RB
    Pak J Med Sci; 2007; 23(6):832-839. PubMed ID: 18846242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
    Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
    Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
    Saif MW
    Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
    Tsutsui M; Yamamoto S; Yoshikawa Y; Nakanishi R; Takano K; Osumi K; Akatsu T; Yoneyama K; Nakagawa M; Kanai T
    Int Cancer Conf J; 2018 Oct; 7(4):125-129. PubMed ID: 31149530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed Presentation of DPD Deficiency in Colorectal Cancer.
    Law L; Rogers J; Eng C
    J Adv Pract Oncol; 2014 May; 5(3):205-10. PubMed ID: 25089219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
    Maillard M; Eche-Gass A; Ung M; Brice A; Marsili S; Montastruc M; Puisset F; Thomas F
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):579-583. PubMed ID: 33587160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.
    Del Re M; Quaquarini E; Sottotetti F; Michelucci A; Palumbo R; Simi P; Danesi R; Bernardo A
    Pharmacogenomics; 2016; 17(1):5-9. PubMed ID: 26651493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
    Wang L; Howlett S; Essapen S
    Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
    Magnani E; Farnetti E; Nicoli D; Casali B; Savoldi L; Focaccetti C; Boni C; Albini A; Banzi M
    Intern Emerg Med; 2013 Aug; 8(5):417-23. PubMed ID: 23585145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.